- Home
- QURE vs GPI Comparison
QURE vs GPI Comparison
Compare QURE & GPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | GPI |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | 2013 | 1997 |
Fundamental Metrics
Financial Performance| Metric | QURE | GPI |
|---|---|---|
| Price | $43.04 | $278.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $45.00 | ★ $447.14 |
| AVG Volume (30 Days) | ★ 1.1M | 186.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ 19.50 |
| Revenue | $13,107,000.00 | ★ $11,123,721,000.00 |
| Revenue This Year | $126.12 | $3.41 |
| Revenue Next Year | $200.43 | $3.10 |
| P/E Ratio | ★ N/A | $14.27 |
| Revenue Growth | N/A | ★ 2.17 |
| 52 Week Low | $8.73 | $249.54 |
| 52 Week High | $71.50 | $470.48 |
Technical Indicators
Market Signals| Indicator | QURE | GPI |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 52.81 |
| Support Level | $39.50 | $279.10 |
| Resistance Level | $51.09 | $343.25 |
| Average True Range (ATR) | 2.05 | 9.68 |
| MACD | -0.66 | 3.01 |
| Stochastic Oscillator | 21.68 | 57.17 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About GPI Group 1 Automotive Inc.
Group 1 owns and operates 32 collision centers and over 250 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 106 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.